



# Enspryng in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

NEUROLOGY · NMOSD (AQP4-IGG+)

## The clinical situation

Enspryng (satralizumab-mwge) is an FDA-approved humanised anti-IL-6 receptor monoclonal antibody for NMOSD in adults who are AQP4 antibody positive, manufactured by Genentech (Roche). Uniquely among approved NMOSD biologics it is administered subcutaneously as 120 mg at weeks 0, 2, and 4 (induction), then every four weeks (maintenance). Eligibility requires confirmed AQP4-IgG seropositivity and a pre-treatment screening bundle (hepatitis B, tuberculosis, LFTs, lipid panel, vaccinations). The first dose is typically administered or observed in a clinical setting; maintenance can be home-administered once technique is established.

## The pathway, 5 steps

- 1 Consultation with neurology.** AQP4-IgG confirmation, NMOSD diagnosis, pre-treatment screening (HBV, TB, LFTs, lipids, vaccinations) documented.
- 2 SFDA named-patient application.** Physician files clinical letter, patient identifier, and product details.
- 3 US-side sourcing.** Reserve Meds coordinates through our US-licensed DSCSA-compliant specialty wholesale partner.
- 4 Cold-chain shipment.** Enspryng ships at 2–8°C with continuous temperature monitoring.
- 5 Arrival & administration.** Treating centre administers/observes first dose; subsequent doses may be home-administered under supervision.

## Indicative economics

**Reference US cash-pay range:** USD 200,000–300,000 annualised (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

## Indicative first-dose timing

**7–14 days** from a complete SFDA application to first dose, once cohort intake opens — screening lead-time may extend this. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review, keyed to the AQP4-IgG-positive NMOSD rationale. **Logistics.** 2–8°C cold-chain coordination. **Concierge case lead.** Named point of contact across induction and four-weekly maintenance. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Enspryng × Saudi Arabia first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/enspryng-saudi-arabia.html](https://reservemed.com/access-guides/enspryng-saudi-arabia.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team